By Cecilia Butini
On Thursday, Roche Holding AG reported that first-half profit declined, although sales rose, driven by the diagnostics division.
The largest Swiss pharmaceutical company reported net profit for the period of 7.80 billion Swiss francs ($ 8.50 billion), up from 8.08 billion Swiss francs a year earlier, with sales rising to 30.71 billion Swiss francs from 29 , 28 billion Swiss francs.
Operating income was CHF 10.08 billion, up from CHF 10.64 billion in the previous year.
Sales in the diagnostics division were up 51% on the back of strong demand for Covid-19 tests and strong routine testing dynamics, the company said.
In the pharmaceutical division, on the other hand, sales fell 3% in the first half, hit by the pandemic in the first quarter, followed by some growth in the second, Roche said.
Roche reaffirmed its full-year outlook, saying it expects sales to grow in the low to medium single digits at constant exchange rates, as well as general earnings per share growth in line with sales. He added that he expects further dividend increases in Swiss francs.
Email Cecilia Butini at [email protected]